Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2013 3
2014 2
2015 3
2016 13
2017 5
2018 4
2019 12
2020 10
2021 11
2022 4
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Results by year

Filters applied: . Clear all
Page 1
KDM5B predicts temozolomide-resistant subclones in glioblastoma.
Ullrich V, Ertmer S, Baginska A, Dorsch M, Gull HH, Cima I, Berger P, Dobersalske C, Langer S, Meyer L, Dujardin P, Kebir S, Glas M, Blau T, Keyvani K, Rauschenbach L, Sure U, Roesch A, Grüner BM, Scheffler B. Ullrich V, et al. Among authors: kebir s. iScience. 2023 Dec 3;27(1):108596. doi: 10.1016/j.isci.2023.108596. eCollection 2024 Jan 19. iScience. 2023. PMID: 38174322 Free PMC article.
Correlation of the apparent diffusion coefficient with the standardized uptake value in meningioma of the skull plane using [68]Ga-DOTATOC PET/MRI.
Milosevic A, Styczen H, Haubold J, Kessler L, Grueneisen J, Li Y, Weber M, Fendler WP, Morawitz J, Damman P, Wrede K, Kebir S, Glas M, Guberina M, Blau T, Schaarschmidt BM, Deuschl C. Milosevic A, et al. Among authors: kebir s. Nucl Med Commun. 2023 Dec 1;44(12):1106-1113. doi: 10.1097/MNM.0000000000001774. Epub 2023 Oct 12. Nucl Med Commun. 2023. PMID: 37823259
Are we providing best-available care to newly diagnosed glioblastoma patients? Systematic review of phase III trials in newly diagnosed glioblastoma 2005-2022.
Oster C, Schmidt T, Agkatsev S, Lazaridis L, Kleinschnitz C, Sure U, Scheffler B, Kebir S, Glas M. Oster C, et al. Among authors: kebir s. Neurooncol Adv. 2023 Sep 4;5(1):vdad105. doi: 10.1093/noajnl/vdad105. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37811538 Free PMC article. Review.
Feasibility and tolerability of trofosfamide and etoposide in progressive glioblastoma.
Schmidt T, Agkatsev S, Feldheim J, Oster C, Blau T, Sure U, Keyvani K, Kleinschnitz C, Stuschke M, Herrmann K, Deuschl C, Scheffler B, Kebir S, Glas M, Lazaridis L. Schmidt T, et al. Among authors: kebir s. Neurooncol Adv. 2023 Jul 20;5(1):vdad090. doi: 10.1093/noajnl/vdad090. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37547266 Free PMC article.
First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma.
Lazaridis L, Bumes E, Cäcilia Spille D, Schulz T, Heider S, Agkatsev S, Schmidt T, Blau T, Oster C, Feldheim J, Stummer W, Kessler AF, Seidel C, Grauer O, Hau P, Sure U, Keyvani K, Herrlinger U, Kleinschnitz C, Stuschke M, Herrmann K, Deuschl C, Breuer S, Hattingen E, Scheffler B, Kebir S, Glas M. Lazaridis L, et al. Among authors: kebir s. Neurooncol Adv. 2022 Aug 24;4(1):vdac137. doi: 10.1093/noajnl/vdac137. eCollection 2022 Jan-Dec. Neurooncol Adv. 2022. PMID: 36284931 Free PMC article.
A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma.
Kebir S, Ullrich V, Berger P, Dobersalske C, Langer S, Rauschenbach L, Trageser D, Till A, Lorbeer FK, Wieland A, Wilhelm-Buchstab T, Ahmad A, Fröhlich H, Cima I, Prasad S, Matschke J, Jendrossek V, Remke M, Grüner BM, Roesch A, Siveke JT, Herold-Mende C, Blau T, Keyvani K, van Landeghem FKH, Pietsch T, Felsberg J, Reifenberger G, Weller M, Sure U, Brüstle O, Simon M, Glas M, Scheffler B. Kebir S, et al. Clin Cancer Res. 2023 Jan 17;29(2):488-500. doi: 10.1158/1078-0432.CCR-22-0611. Clin Cancer Res. 2023. PMID: 36239995 Free PMC article.
Precision neuro-oncology: a pilot analysis of personalized treatment in recurrent glioma.
Lazaridis L, Schmidt T, Oster C, Blau T, Pierscianek D, Siveke JT, Bauer S, Schildhaus HU, Sure U, Keyvani K, Kleinschnitz C, Stuschke M, Herrmann K, Deuschl C, Scheffler B, Kebir S, Glas M. Lazaridis L, et al. Among authors: kebir s. J Cancer Res Clin Oncol. 2023 Jul;149(7):3513-3526. doi: 10.1007/s00432-022-04050-w. Epub 2022 Aug 12. J Cancer Res Clin Oncol. 2023. PMID: 35953681 Free PMC article.
Electrolyte and renal disorders in patients with newly diagnosed glioblastoma.
Pierscianek D, Oppong MD, Ahmadipour Y, Rauschenbach L, Michel A, Kebir S, Dammann P, H Wrede K, Glas M, Hense J, Pöttgen C, Sure U, Jabbarli R. Pierscianek D, et al. Among authors: kebir s. Future Oncol. 2021 Dec;17(34):4711-4719. doi: 10.2217/fon-2020-1312. Epub 2021 Oct 21. Future Oncol. 2021. PMID: 34672208
66 results